OH

Optometry Hub

Chlamydial Conjunctivitis

Evidence-based assessment and management of Chlamydia trachomatis ocular infection — from adult inclusion conjunctivitis to trachoma and neonatal disease. Comprehensive guide covering etiology, pathogenesis, classification, diagnosis, and treatment protocols for optometry practice.

Last updated: March 2026

Everted lower tarsal conjunctivaPale avascularfolliclesConjunctivalhyperaemiaAnterior segment — adult inclusion conjunctivitisLNInferior fornixfolliclesSuperiorlimbal pannusMucopurulentdischargePreauricularlymph node

Left: Everted lower tarsal conjunctiva showing dense inferior follicles — pale, dome-shaped, avascular. Right: Adult inclusion conjunctivitis with follicular reaction, superior limbal pannus, mucopurulent discharge, and preauricular lymphadenopathy.

Chlamydial conjunctivitis encompasses a spectrum of ocular infections caused by the obligate intracellular bacterium Chlamydia trachomatis. It manifests in three distinct clinical forms determined by the infecting serovar: (1) trachoma (serovars A–C) — the world’s leading infectious cause of blindness, responsible for an estimated 1.9 million cases of visual impairment globally and endemic in resource-limited communities across sub-Saharan Africa, parts of Asia, the Middle East, and Oceania; (2) adult inclusion conjunctivitis (AIC) / oculogenital disease (serovars D–K) — a sexually transmitted infection (STI) affecting sexually active adults, the most common form encountered in high-income countries; and (3) neonatal inclusion conjunctivitis (serovars D–K) — acquired during passage through an infected birth canal, the most common infectious cause of neonatal conjunctivitis in the developed world. All three forms share the microbiological agent and broad tissue tropism for columnar and transitional epithelium but differ profoundly in epidemiology, clinical presentation, complications, and management. Chlamydial eye disease is frequently under-recognised in optometric practice because of its chronic, indolent course, and the absence of a pathognomonic feature distinguishing it at a glance from viral follicular conjunctivitis.

The Causative Organism

Chlamydia trachomatis is a gram-negative, obligate intracellular bacterium that cannot synthesise its own ATP and is entirely dependent on the host cell’s metabolic machinery for replication. It exists in two morphological forms: (1) the metabolically inert elementary body (EB) — the infectious extracellular particle, 0.3 µm in diameter, that attaches to and enters host epithelial cells; and (2) the metabolically active reticulate body (RB) — the intracellular replicative form that divides by binary fission within a membrane-bound vacuole (inclusion). After 48–72 hours, RBs condense back into EBs and the host cell ruptures, releasing hundreds of new EBs. This unique intracellular lifecycle accounts for the organism’s resistance to β-lactam antibiotics and its ability to establish persistent chronic infection.

Serovars and Clinical Disease

Serovar GroupSerovarsOcular DiseaseTransmission Route
Trachoma biovarA, B, Ba, CTrachoma — follicular keratoconjunctivitis; cicatricial blindnessEye-to-eye; eye-to-hand-to-eye; flies; fomites (endemic communities)
Oculogenital biovarD, E, F, G, H, I, J, KAdult inclusion conjunctivitis; neonatal inclusion conjunctivitisSexual contact (genital ↔ eye); birth canal (neonates); autoinoculation
Lymphogranuloma venereum (LGV) biovarL1, L2, L3Parinaud oculoglandular syndrome; severe ulcerative conjunctivitis (rare)Sexual contact; invasive systemic disease

Transmission Mechanisms

  • Trachoma (A–C): Direct contact with ocular or nasal discharge from infected individuals; fomite transmission (shared towels, clothing); eye-seeking fly (Musca sorbens) mechanical vector in endemic regions; crowded living conditions and limited access to clean water dramatically amplify transmission. Repeated re-infection throughout childhood is the driver of cicatricial disease
  • Adult inclusion conjunctivitis (D–K): Most commonly by autoinoculation from concurrent genital chlamydial infection (fingers to eye); less frequently by direct genital-to-ocular transmission during sexual activity; sharing of cosmetics, eye drops, or towels (uncommon); no known insect vector
  • Neonatal inclusion conjunctivitis (D–K): Vertical transmission during vaginal delivery from a mother with active cervical C. trachomatis infection; risk of transmission from infected mother to neonate is approximately 30–50%; caesarean section dramatically reduces but does not eliminate transmission risk (amniotic fluid infection can occur)

Intracellular Infection Cycle

  1. Attachment and entry: Elementary bodies attach to epithelial cell surface receptors (heparan sulfate proteoglycans and MOMP — major outer membrane protein) via receptor-mediated endocytosis. In conjunctival epithelium, EBs specifically infect columnar and transitional epithelial cells of the tarsal and forniceal conjunctiva
  2. Inclusion formation: Once internalised, the endosomal vacuole is modified to form the chlamydial inclusion — a membrane-bound compartment that resists lysosomal fusion through active interference with host cell vesicular trafficking (secretion of Inc proteins). EBs differentiate into metabolically active RBs within 8–12 hours
  3. Replication: RBs replicate by binary fission within the expanding inclusion for 24–48 hours; a single inclusion can contain 500–1000 RBs by mid-cycle. Replicating RBs are entirely dependent on host cell ATP, amino acids, and lipid precursors
  4. Re-differentiation and cell lysis: At 48–72 hours post-infection, RBs condense back into EBs. The mature inclusion eventually ruptures the host cell, releasing hundreds of new infectious EBs; some inclusions may extrude without cell lysis (extrusion pathway), enabling chronic persistent infection without overt cell death
  5. Persistent infection: Under conditions of stress (antibiotic exposure, interferon-γ exposure, nutrient deprivation), C. trachomatis can enter a state of persistence — enlarged, aberrant RBs that are metabolically active but non-replicating; persistent forms are resistant to antibiotics and explain treatment failures and recurrences

Immune Response and Tissue Damage

The conjunctival response to C. trachomatis infection involves both innate and adaptive immunity, and it is the repeated activation of the adaptive immune response — rather than the organism itself — that drives the cicatricial damage of trachoma.

  • Innate response: Infected conjunctival epithelial cells release IL-1β, IL-6, IL-8, and TNF-α via TLR2/TLR4 signalling; neutrophils are recruited first, producing the initial mucopurulent discharge and follicle formation
  • Follicle formation: The hallmark pathological feature; follicles are organised lymphoid aggregates in the conjunctival substantia propria consisting of a germinal centre (B-cells, activated macrophages) surrounded by T-lymphocyte zones; they represent a classic delayed-type hypersensitivity response to chlamydial antigens, particularly heat shock proteins (HSP60, HSP10)
  • Th1-driven immunopathology: IFN-γ–producing CD4+ Th1 cells are the primary mediators of chlamydial immunity; paradoxically, repeated IFN-γ exposure drives both bacterial clearance and, in chronic infection, pathological collagen deposition via TGF-β and fibroblast activation
  • Chlamydial HSP60 and molecular mimicry: C. trachomatis HSP60 shares significant sequence homology with human HSP60; repeated exposure leads to autoimmune cross-reactivity that amplifies conjunctival fibrosis, contributing to trachomatous scarring
  • Cicatrisation (trachoma-specific): Repeated cycles of infection and healing produce progressive subepithelial fibrosis, tarsal plate scarring (Arlt’s line), entropion, trichiasis, and ultimately corneal abrasion leading to opacification. Matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) are dysregulated, tipping the balance toward net collagen accumulation

WHO Simplified Trachoma Grading System (SAFE Strategy)

GradeDefinitionClinical Feature
TF — Trachomatous Inflammation, FollicularActive disease; ≥5 follicles (≥0.5 mm) in the central upper tarsal conjunctivaPale, avascular, dome-shaped follicles on everted upper lid; mild injection
TI — Trachomatous Inflammation, IntensePronounced inflammatory thickening of the upper tarsal conjunctiva; >50% of deep tarsal vessels obscured by papillary hypertrophyOedematous, velvety tarsal conjunctiva; papillary hypertrophy obscuring follicles; mucopurulent discharge
TS — Trachomatous ScarringScarring of the tarsal conjunctiva; white lines, bands or sheets (Arlt’s line)Subepithelial fibrosis visible as white fibrous bands running horizontally across the tarsal plate; inactive disease
TT — Trachomatous TrichiasisAt least one misdirected eyelash touching the globe, or evidence of recent epilationInturned lashes abrading the cornea; secondary corneal erosions; photophobia
CO — Corneal OpacityCorneal opacity over the pupil; visually significantCentral corneal scar reducing visual acuity; end-stage blinding trachoma

Adult Inclusion Conjunctivitis (AIC)

  • Acute AIC (<3 weeks): Follicular conjunctivitis with mucopurulent discharge; often unilateral at onset; may be mistaken for viral or bacterial conjunctivitis; preauricular lymphadenopathy common
  • Subacute / chronic AIC (3 weeks – 12 months): The most common presentation at optometric encounters; persistent follicular conjunctivitis refractory to topical antibiotics; superior limbal follicles and early micropannus; frequently bilateral by this stage
  • Chronic AIC (>12 months, untreated): Inferior and superior tarsal scarring; Herbert’s pits (limbal follicle scars); superior pannus; rare progression to trachoma-like cicatrisation in immunocompromised patients

Neonatal Inclusion Conjunctivitis

  • Onset: Typically 5–14 days after birth (distinguishes from gonococcal onset at 2–5 days and chemical at 24 hours)
  • Bilateral or unilateral: Usually bilateral; may begin unilateral; mucopurulent discharge; lid oedema; no follicles in the first 2–3 months of life (immature lymphoid tissue); papillary reaction predominates in neonates
  • Extraocular involvement: 30–50% develop chlamydial pneumonitis if untreated; otitis media and nasopharyngeal infection may also occur

Adult Inclusion Conjunctivitis

  • Young sexually active adults: Peak incidence ages 15–35 years; AIC is one of the most common STI-associated ocular conditions in high-income countries
  • New or multiple sexual partners: The primary risk factor for genital chlamydial infection, which is the prerequisite for AIC; rate of genital chlamydia in 15–24-year-olds is 2–3% in many populations
  • Concurrent genital chlamydial infection: 25–50% of patients with AIC have co-existing cervicitis or urethritis that is often asymptomatic; failure to recognise and treat the genital reservoir leads to re-infection and treatment failure
  • No or inconsistent barrier contraception: Condom use significantly reduces genital chlamydial transmission
  • Autoinoculation practices: Touching the eyes after touching the genitals without hand washing
  • Contact lens wear: Contact lenses worn during an episode of genital chlamydial infection may introduce EBs to the conjunctival surface; lens wear also provides a surface for EB adherence

Trachoma

  • Poverty and resource-limited settings: Trachoma is inextricably linked to poverty; lack of clean water, sanitation, and hygiene facilities drives transmission
  • Age under 10 years: Children are the primary reservoir of active trachoma (TF/TI) in endemic communities; repeatedly re-infected children develop increasingly severe inflammation; cicatricial disease manifests in adulthood after decades of repeated infection
  • Female sex: Women are 2–3× more likely than men to develop cicatricial trachoma (TS, TT); proposed mechanisms include more frequent close contact with infected children (care-giving role) and possible hormonal differences in mucosal immunity
  • Endemic regions: 44 countries currently endemic; highest burden in Ethiopia, Nigeria, South Sudan, Chad, Niger, and parts of Southeast Asia and the Pacific
  • Fly density (Musca sorbens): Eye-seeking flies mechanically transfer ocular discharge between individuals; fly control is part of the WHO SAFE strategy
  • Household crowding and shared sleeping: Proximity facilitates direct contact transmission; households with index cases of active trachoma have 3–4× higher rates of infection in contacts

Neonatal Disease

  • Untreated maternal cervical chlamydial infection: The definitive risk factor; a neonate born vaginally to an untreated infected mother has a 30–50% risk of acquiring conjunctival infection
  • Lack of antenatal screening: Routine antenatal chlamydia screening and treatment programs in high-income countries have dramatically reduced neonatal incidence; absence of screening is the primary risk factor in low-income settings
  • Vaginal delivery: Risk significantly higher than with caesarean section; however, even caesarean delivery does not entirely eliminate risk if membranes ruptured before delivery

Adult Inclusion Conjunctivitis (Serovars D–K)

  • Follicular conjunctivitis — inferior fornix predominance: The hallmark sign; pale, avascular, dome-shaped follicles (≥0.5 mm) distributed predominantly in the inferior fornix and lower tarsal conjunctiva; in chronic disease, follicles extend to the upper tarsus, bulbar conjunctiva, and limbus. Follicles are distinguished from papillae by their avascular nature (no central vessel), pale or yellowish-grey colour, and soft, gelatinous consistency
  • Conjunctival hyperaemia: Diffuse injection of bulbar and palpebral conjunctiva; more pronounced around follicles and in the inferior fornix; may resemble viral conjunctivitis
  • Mucopurulent discharge: Moderate amount; more purulent than the watery discharge of viral conjunctivitis; less copious than gonococcal; yellow-green in colour; lid matting on waking
  • Preauricular lymphadenopathy: Present in 50–90% of AIC cases; typically tender; a key clinical sign that distinguishes infectious follicular conjunctivitis from allergic follicular reactions
  • Superior limbic follicles and micropannus: In subacute and chronic cases, follicles appear at the superior limbus; progressive fibrovascular ingrowth (micropannus) extends 1–2 mm onto the superior cornea; earlier and more prominent in trachoma but can occur in chronic AIC
  • Superficial punctate keratopathy (SPK): Fine punctate epithelial erosions, predominantly superior; reflects corneal involvement by adjacent limbal and conjunctival inflammation
  • Subepithelial corneal infiltrates: Small grey subepithelial infiltrates in the superior cornea (reminiscent of adenoviral EKC); indicative of active corneal immunological reaction; do not stain with fluorescein unless erosion present

Trachoma (Serovars A–C)

  • Upper tarsal follicles and papillae (TF/TI): Active trachoma predominantly involves the upper tarsal conjunctiva (inverse of AIC); follicles mixed with papillary hypertrophy; in intense disease (TI), the tarsal plate becomes thickened, oedematous, and velvety with obscured vessels
  • Arlt’s line (TS): Pathognomonic of trachomatous scarring; a horizontal white fibrous line or band running across the upper tarsal plate at the junction of the upper one-third and lower two-thirds; represents subepithelial fibrosis from healed follicles
  • Herbert’s pits: Small saucer-shaped depressions at the superior limbus representing healed limbal follicle scars; pathognomonic of previous trachoma or chronic chlamydial conjunctivitis; visible on slit lamp as punctate limbal depressions
  • Superior pannus: Fibrovascular ingrowth from the superior limbus onto the corneal surface; progresses centrally with repeated infection; early pannus is superficial and partially reversible; dense central pannus causes irreversible vision loss
  • Trachomatous trichiasis (TT): Inturned eyelashes contacting the globe; caused by progressive tarsal plate scarring deforming the lid margin; produces corneal abrasion, pain, photophobia, and tearing; the proximate cause of corneal opacification in trachoma
  • Entropion: Inward rotation of the entire eyelid margin from advanced tarsal scarring; usually upper lid; potentiates trichiasis; requires surgical correction
  • Corneal opacity (CO): End-stage trachoma; dense central stromal scar reducing VA to <6/60; caused by repeated corneal abrasion from trichiasis over years to decades

Neonatal Inclusion Conjunctivitis

  • Bilateral lid oedema and conjunctival injection with mucopurulent discharge
  • Papillary reaction (not follicular — follicles do not form in the first 2–3 months of life owing to immature conjunctival lymphoid tissue)
  • Pseudomembrane formation may occur in severe cases; chemosis
  • Corneal involvement is uncommon unless diagnosis and treatment are delayed

Adult Inclusion Conjunctivitis

  • Chronic red eye: The most common presenting complaint; patients report persistent or recurrent redness lasting weeks to months, often unresponsive to over-the-counter antibiotic or antihistamine drops
  • Mucopurulent discharge: Moderate discharge; morning lid crusting; patients may attribute to “infected eye” or hay fever; discharge is less copious than bacterial conjunctivitis
  • Foreign body sensation and irritation: Constant grittiness; worse in the morning; reflects conjunctival inflammation and tear film instability secondary to goblet cell disruption
  • Mild photophobia: Present when corneal involvement (SPK, subepithelial infiltrates) occurs; more pronounced with limbal follicles
  • Tender preauricular swelling: Patients may notice a tender lump anterior to the tragus of the ear; more commonly elicited on clinical examination than spontaneously reported
  • Mildly reduced visual acuity: From mucoid discharge on the cornea or, in chronic cases, from subepithelial infiltrates; frank vision loss is uncommon in AIC
  • Asymptomatic genital infection: Up to 70% of women and 50% of men with genital chlamydial infection are entirely asymptomatic; patients may not spontaneously report genital symptoms unless directly asked

Trachoma

  • Active trachoma (TF/TI) in children: Mild irritation; mucopurulent discharge; may be asymptomatic in early stages; children in endemic areas often present with chronic eye discharge normalised by their community
  • Trichiasis (TT): Intense photophobia; constant pain and foreign body sensation from lash–corneal contact; epiphora; blepharospasm; patients in endemic communities may spend hours daily epilating lashes to reduce pain
  • Advanced corneal opacity (CO): Severely reduced or absent vision; presents in adults 40–60 years, representing decades of cumulative damage from childhood infection

Ocular Complications — Adult Inclusion Conjunctivitis

  • Corneal scarring (rare in treated AIC): Subepithelial fibrosis from recurrent subepithelial infiltrates in chronic untreated disease; superficial and central scars reducing visual acuity
  • Superior corneal pannus: Fibrovascular ingrowth from the superior limbus; in chronic AIC, can extend 2–3 mm onto the cornea; partially reversible after treatment; persistent pannus leaves a grey fibrovascular scar
  • Herbert’s pits: Permanent limbal scars after resolution of limbal follicles; no functional visual significance but indicate prior/chronic chlamydial infection
  • Chronic follicular conjunctivitis: Without systemic antibiotic treatment, AIC can persist for 12–24 months, progressively damaging the ocular surface; topical antibiotics alone are ineffective
  • Dry eye disease: Goblet cell destruction from chronic conjunctival inflammation reduces mucin production; secondary aqueous-deficient dry eye from lacrimal gland inflammation

Ocular Complications — Trachoma

  • Trachomatous blindness: Trachoma is the world’s leading infectious cause of blindness; an estimated 1.9 million people are visually impaired or blind from trachoma, with over 7.5 million at immediate risk from trichiasis
  • Entropion and trichiasis: Cicatricial inturning of the eyelid; lash–corneal contact produces chronic mechanical abrasion; the direct proximate cause of corneal opacification
  • Corneal vascularisation and opacification: Progressive pannus followed by dense stromal scarring; once established, corneal opacification is irreversible without keratoplasty
  • Xerophthalmia (dry eye): Goblet cell and accessory lacrimal gland destruction from cicatricial disease; severe dry eye compounding corneal damage from trichiasis
  • Symblepharon and forniceal obliteration: In end-stage cicatricial trachoma; restricts ocular motility and makes prosthetic correction impossible
  • Corneal secondary infection: Compromised corneal epithelium from trichiasis is vulnerable to bacterial superinfection (especially Haemophilus influenzae, Streptococcus pneumoniae in endemic areas)

Neonatal Complications

  • Chlamydial pneumonitis: The most serious complication of neonatal chlamydial infection; develops at 4–12 weeks of age; afebrile staccato cough with tachypnoea; interstitial pneumonia on chest X-ray; can be fatal if untreated; affects 30–50% of untreated neonates with chlamydial conjunctivitis
  • Otitis media and nasopharyngeal infection: Ascending spread of C. trachomatis from conjunctival surface; less common than pneumonitis
  • Corneal involvement: Rare in neonatal AIC when promptly treated; possible with delayed diagnosis

Genital Chlamydial Infection (Serovars D–K)

Chlamydia trachomatis is the most common bacterial sexually transmitted infection globally, with an estimated 127 million new cases annually (WHO 2020). The vast majority of patients presenting with AIC have concurrent — often asymptomatic — genital infection that is the source of ocular inoculation. Key systemic genital manifestations include:

  • Women: Cervicitis (mucopurulent cervical discharge, post-coital bleeding); pelvic inflammatory disease (PID) — salpingitis, endometritis; tubal scarring leading to ectopic pregnancy and infertility; Fitz-Hugh–Curtis syndrome (perihepatitis causing right upper quadrant pain)
  • Men: Urethritis (dysuria, urethral discharge — often mild or absent); epididymo-orchitis; reactive arthritis (formerly Reiter syndrome: urethritis, arthritis, conjunctivitis/uveitis triad)
  • Both sexes: Rectal chlamydial infection in those who practise receptive anal intercourse; pharyngeal infection; systemic dissemination is rare except in the LGV biovar

Reactive Arthritis (Formerly Reiter Syndrome)

C. trachomatis is a well-established trigger for reactive arthritis — a seronegative spondyloarthropathy characterised by the classic triad of non-infectious urethritis, asymmetric oligoarthritis (predominantly lower limbs), and conjunctivitis or uveitis. Anterior uveitis is more common than conjunctivitis in established reactive arthritis. Keratoderma blenorrhagica (hyperkeratotic skin lesions) and circinate balanitis may also occur. HLA-B27 positivity predicts a more severe and recurrent course. The clinician encountering unilateral anterior uveitis in a young sexually active adult should consider reactive arthritis and chlamydial infection in the differential.

Lymphogranuloma Venereum (LGV — Serovars L1–L3)

LGV serovars are more invasive than urogenital serovars, penetrating submucosal lymphatics and producing systemic disease. Ocular involvement is rare but includes Parinaud oculoglandular syndrome — unilateral granulomatous conjunctivitis with marked ipsilateral preauricular and cervical lymphadenopathy; the conjunctival granuloma may ulcerate. Systemic features include inguinal lymphadenopathy (bubo formation), proctitis, and, in untreated cases, systemic sepsis.

Public Health Implications

Identification of AIC in optometric practice carries significant public health obligations. Partner notification and treatment are mandatory to break the transmission cycle. Sexual health referral is essential. In Singapore, chlamydial genital infection is a notifiable STI under the Infectious Diseases Act. Trachoma is a notifiable disease in many countries and triggers WHO-coordinated SAFE strategy interventions at the community level.

Clinical Suspicion — When to Suspect Chlamydial Conjunctivitis

  • Any young sexually active adult (15–35 years) with a chronic follicular conjunctivitis lasting >2–4 weeks
  • Conjunctivitis refractory to topical antibiotic therapy (topical antibiotics are ineffective for chlamydial infection)
  • Follicular conjunctivitis with preauricular lymphadenopathy (present in 50–90% of AIC)
  • Inferior fornix follicles with superior limbal follicles or micropannus
  • Any conjunctivitis in a neonate aged 5–14 days
  • Patients from trachoma-endemic regions presenting with tarsal scarring, Arlt’s line, Herbert’s pits, or trichiasis
  • Conjunctivitis associated with known or suspected STI in either the patient or their partner

History

  • Duration of conjunctivitis; response (or lack thereof) to prior topical antibiotic or antiviral therapy
  • Sexual history — number of partners, barrier contraception use, history of STIs
  • Genital symptoms: urethral discharge, dysuria, pelvic pain, vaginal discharge, post-coital bleeding
  • Country of birth and travel history (trachoma endemic region?)
  • History of similar episodes and treatments
  • Neonates: maternal antenatal care, STI history, mode of delivery
  • Systemic symptoms: arthritis, skin lesions, urogenital symptoms (reactive arthritis?)

Clinical Examination

1. Lid Eversion (Upper and Lower):

  • Upper tarsal plate: follicles, papillae, subepithelial fibrosis (Arlt’s line in trachoma)
  • Lower tarsal plate and fornix: inferior follicle distribution (AIC predominates inferiorly)
  • Note the size, distribution, and character of follicles vs. papillae

2. Slit Lamp Biomicroscopy:

  • Superior limbus: Inspect for limbal follicles, Herbert’s pits, and pannus; Trantas dots (if VKC co-existing)
  • Cornea (white light): Superior pannus, subepithelial infiltrates, stromal scarring
  • Cornea (fluorescein, cobalt blue): PEE pattern (superior SPK in chlamydial), epithelial defects; confirm trichiasis corneal abrasion pattern in trachoma
  • Discharge: Assess character — mucoid, mucopurulent; Gram stain / Giemsa can be performed on expressed discharge
  • Lid margin: Entropion, trichiasis, blepharitis
  • Anterior chamber: Cells and flare to exclude concurrent uveitis (reactive arthritis)

3. Preauricular Node Palpation:

  • Palpate anterior to the tragus of the ear bilaterally; tender lymphadenopathy present in majority of AIC and many viral conjunctivitis cases; absent in bacterial and allergic conjunctivitis

4. Intraocular Pressure:

  • Measure IOP to exclude concurrent angle-closure glaucoma and assess baseline before any steroid use

Laboratory Investigations (Essential for Confirmation)

  • Nucleic acid amplification test (NAAT) — conjunctival swab: Gold standard for diagnosis of AIC; sensitivity >90%, specificity >98%; conjunctival swab taken from the lower fornix and/or everted upper lid (use manufacturer-specific transport medium); NAAT detects C. trachomatis DNA/RNA and is the test of choice in all age groups
  • Concurrent urogenital NAAT: Cervical swab (women) or first-void urine / urethral swab (men) for genital chlamydia; mandatory in all adults with AIC; positive genital NAAT confirms the diagnosis and guides partner notification and management
  • Conjunctival scraping — Giemsa staining: Intracytoplasmic inclusion bodies (Halberstaedter–Prowazek bodies) in conjunctival epithelial cells; historically diagnostic but sensitivity only 30–70%; now superseded by NAAT in routine practice; still used in resource-limited settings
  • Direct fluorescent antibody (DFA) test: Detects chlamydial antigens on conjunctival scrape smears; sensitivity 70–85%; may be used where NAAT is unavailable; requires skilled interpretation
  • Culture: Gold standard historically; sensitive but technically demanding, slow (3–7 days), requires tissue culture facilities; now replaced by NAAT for routine clinical use; still used for medico-legal purposes
  • Neonatal investigations: NAAT of conjunctival swab is preferred; additionally, nasopharyngeal and rectal swabs to assess systemic burden; maternal cervical NAAT to confirm source
  • Screening for co-infections: All adults with AIC should be offered concurrent testing for gonorrhoea (NAAT), syphilis (RPR/TPHA), HIV, and hepatitis B — the full STI panel is standard of care at sexual health services

Trachoma Field Diagnosis

In endemic communities, trachoma is diagnosed clinically using the WHO simplified grading system applied under binocular loupe (×2.5 magnification) or slit lamp; laboratory confirmation is not routinely required for public health interventions. NAAT is used in research and surveillance contexts to determine community prevalence thresholds that trigger the SAFE strategy interventions.

Singapore Optometry Scope Note: Optometrists in Singapore may perform a full anterior segment assessment including slit lamp biomicroscopy, lid eversion, fluorescein staining, and IOP measurement. Fundus assessment is performed using non-contact slit lamp biomicroscopy with a condensing lens or approved diagnostic equipment — dilation is not performed by optometrists in Singapore. Prescribing systemic antibiotics (azithromycin, doxycycline) is outside optometric scope; all confirmed or suspected chlamydial conjunctivitis must be referred to a medical doctor or ophthalmologist for systemic treatment. Sexual health referral for partner notification is mandatory. Chlamydial genital infection is notifiable under the Singapore Infectious Diseases Act. Optometrists should take the conjunctival NAAT swab where training and resources allow, then refer for definitive systemic management.

Systemic Antibiotic Therapy — Adult Inclusion Conjunctivitis

Key principle: Topical antibiotics alone are completely ineffective for chlamydial conjunctivitis. Systemic antibiotic therapy is mandatory to eradicate the conjunctival, genital, and pharyngeal reservoirs and prevent reinfection. All sexual partners within the preceding 60 days must be treated simultaneously.

First-Line Regimens:

  • Azithromycin 1 g oral single dose: First-line preferred regimen; high patient acceptability due to single dose; effective for urogenital serovars (D–K); achieves tissue concentrations 100–200× serum levels; cure rates >97% for uncomplicated genital and ocular chlamydial infection; safe in pregnancy
  • Doxycycline 100 mg oral BD for 7 days: Alternative first-line (some guidelines prefer doxycycline as primary due to evidence of superior bacteriological cure for urogenital chlamydia); equally effective; avoid in pregnancy; requires full 7-day course compliance; preferable for suspected concurrent Mycoplasma genitalium or if macrolide resistance is a concern

Alternative Regimens:

  • Erythromycin 500 mg QDS for 7 days: Less well-tolerated due to GI side effects; preferred in pregnancy when azithromycin cannot be used; bacteriostatic mechanism means full course compliance is critical
  • Ofloxacin 300 mg BD for 7 days: Fluoroquinolone alternative; avoid in pregnancy; efficacy comparable to doxycycline in randomised trials
  • Levofloxacin 500 mg OD for 7 days: Once-daily fluoroquinolone; similar efficacy to ofloxacin; preferred in patients with poor compliance for twice-daily regimens

Pregnancy and Neonatal Considerations:

  • Pregnant women: Azithromycin 1 g single dose (safest option in pregnancy); amoxicillin 500 mg TDS for 7 days (alternative); avoid doxycycline, fluoroquinolones
  • Neonatal inclusion conjunctivitis: Oral erythromycin ethylsuccinate 50 mg/kg/day in 4 divided doses for 14 days (treats both conjunctival and respiratory tract infection, preventing pneumonitis); topical antibiotics alone are insufficient; ophthalmology and paediatric co-assessment mandatory
  • Test of cure: Routine test of cure at 3–4 weeks post-treatment is recommended in pregnancy, neonates, and any case with persistent symptoms

Trachoma — WHO SAFE Strategy

The WHO SAFE strategy provides a comprehensive framework for trachoma elimination as a public health problem:

  • S — Surgery for trichiasis (TT): Bilamellar tarsal rotation (BLTR) or posterior lamellar tarsal rotation (PLTR) — lid surgery to correct entropion and trichiasis; halts corneal abrasion and prevents further opacification; should be performed before advanced corneal scarring develops; reduces risk of further vision loss by approximately 80%
  • A — Antibiotics for active infection (TF/TI): Mass drug administration (MDA) with azithromycin 20 mg/kg single oral dose (maximum 1 g) to entire at-risk communities when trachoma prevalence (TF) ≥10% in children 1–9 years; annual or biannual MDA for 3–5 years; tetracycline 1% eye ointment BD for 6 weeks as alternative in communities where oral azithromycin is unavailable
  • F — Facial cleanliness: Promotion of face washing, particularly in children; ocular and nasal discharge removal reduces fly attraction and direct transmission; evidence from cluster RCTs confirms reduction in TF prevalence with face-washing campaigns
  • E — Environmental improvement: Access to clean water and improved sanitation; latrines to reduce fly breeding; improved household conditions; foundational for sustainable trachoma elimination beyond antibiotic programs

Topical and Adjunctive Therapy

  • Topical tetracycline 1% ointment: Used as adjunct in trachoma MDA programs when systemic azithromycin is unavailable; applied BD for 6 weeks; does not replace systemic therapy for AIC
  • Preservative-free artificial tears: For dry eye and ocular surface support during and after infection; preservative-free formulations avoid BAK toxicity on the compromised conjunctival surface
  • Eyelash epilation: Temporary measure in trachomatous trichiasis pending definitive surgical correction; patients in endemic areas perform this themselves (at significant pain); frequent epilation over years may worsen follicular development of remaining lashes
  • Keratoplasty: Penetrating keratoplasty for visually significant corneal opacity from end-stage trachoma or severe AIC scarring; prognosis guarded in trachoma-related cases due to concurrent dry eye, lid abnormalities, and limbal stem cell compromise; requires control of all active inflammation before surgery

Partner Notification and Sexual Health Referral

  • All sexual contacts within the preceding 60 days must be notified and treated empirically for genital chlamydia, regardless of symptom status
  • Patient referral to a sexual health or genitourinary medicine (GUM) clinic for: (a) STI panel screening (gonorrhoea, syphilis, HIV, hepatitis B); (b) formal partner notification counselling; (c) contraception advice; (d) test of cure in selected cases
  • Patients should abstain from unprotected sexual intercourse for 7 days after a single-dose regimen or until completion of a 7-day regimen and until partners are treated
  • In Singapore, confirmed chlamydial genital infection must be notified to the Ministry of Health under the Infectious Diseases Act

Adult Inclusion Conjunctivitis

With appropriate and timely systemic antibiotic therapy and concurrent partner treatment, the prognosis for AIC is excellent. Ocular symptoms typically resolve within 2–4 weeks of treatment; conjunctival injection and follicles regress within 4–8 weeks. Superior limbal follicles and micropannus may take 2–3 months to fully resolve; Herbert’s pits and any subepithelial fibrosis are permanent but have no clinical visual significance in the absence of central corneal involvement. Reinfection from untreated partners is the most common cause of apparent treatment failure — stressing the absolute necessity of concurrent partner treatment.

Prognostic Summary by Disease Form

FormPrognosisKey Determinant
AIC — treated promptly with systemic antibioticsExcellent — full resolution in 4–8 weeks; no permanent vision lossSystemic antibiotic therapy and concurrent partner treatment
AIC — chronic, untreated (>6 months)Good with treatment; Herbert’s pits, micropannus may persist; corneal scarring rareEventual diagnosis and treatment; no partner re-infection
Neonatal — treated within 1–2 weeks of onsetExcellent — full resolution; prevention of pneumonitisOral erythromycin; ophthalmology and paediatrics co-assessment
Trachoma — active (TF/TI), treated with MDAGood in individuals; community-level control requires sustained MDA + SAFERe-infection from untreated community members
Trachoma — scarring stage (TS/TT), no surgeryPoor without intervention — progressive trichiasis and corneal abrasionAccess to surgical correction (BLTR/PLTR)
Trachoma — corneal opacity (CO)Poor for vision recovery without keratoplasty; high recurrence risk post-keratoplasty in untreated trichiasisPrior trichiasis surgery, dry eye management, specialist keratoplasty
ConditionKey Differentiating FeaturesRed Flags / Action
Adenoviral Conjunctivitis (EKC)Acute onset; watery discharge; prominent follicles; preauricular lymphadenopathy; URTI prodrome; pseudomembrane; subepithelial infiltrates (late); highly contagious; self-limiting in 2–4 weeks; no response to antibiotics; does not require systemic treatmentEKC infiltrates reducing VA → refer; strict infection control
Bacterial ConjunctivitisMucopurulent discharge (more purulent than chlamydial); morning lid matting; papillary reaction (not follicular); responds to topical antibiotics within 5–7 days; no preauricular lymphadenopathy typically; no genital STI associationPersistent >2 weeks despite topical antibiotics → suspect chlamydial; NAAT
Gonococcal ConjunctivitisHyperacute onset (hours); profuse copious purulent discharge; chemosis; corneal penetration risk within 24–48 hours; no follicles; preauricular LN; STI contact history; Gram stain: gram-negative intracellular diplococci; NOT self-limitingOcular emergency — immediate ophthalmology referral; systemic ceftriaxone
Herpes Simplex KeratoconjunctivitisUnilateral; dendritic ulcer on fluorescein (pathognomonic); reduced corneal sensation; periocular vesicles; follicular conjunctivitis; history of cold sores; no genital STI association; responds to topical/oral antiviralsDo NOT apply topical steroids — urgent antiviral therapy; ophthalmology if corneal involved
Molluscum Contagiosum ConjunctivitisChronic follicular conjunctivitis with umbilicated lid nodules; single or multiple waxy pearly lid lesions; follicles from viral shedding into tear film; resolves after nodule removal/curettage; no preauricular LN; no discharge; no STI association (usually)Identify and remove molluscum nodules; immunocompromised if multiple widespread lesions
Contact Dermatoconjunctivitis (Type IV)Chronic inferior follicular/papillary reaction; periocular eczema; history of topical medication (neomycin, BAK, cosmetics); inferior SPK; no preauricular LN; patch test positive; improves on cessation of offending agentWithdraw offending agent; dermatology patch testing
Vernal Keratoconjunctivitis (VKC)Young patients; bilateral; intense itch; giant cobblestone papillae (upper tarsal — not follicles); Trantas dots; shield ulcer risk; seasonal; atopic history; no follicles; no genital STI link; no preauricular LNShield ulcer → urgent ophthalmology; topical ciclosporin / steroid under specialist
Parinaud Oculoglandular SyndromeUnilateral granulomatous conjunctivitis with massive ipsilateral preauricular / submandibular lymphadenopathy (may suppurate); causes: Bartonella henselae (cat scratch), Tularaemia, LGV chlamydia, Yersinia; systemic feverSystemic investigation; infectious disease referral; specific antibiotics by aetiology
Mucous Membrane Pemphigoid (MMP)Older patients; cicatrising conjunctivitis with symblepharon and forniceal shortening; no follicles; no infectious cause; autoimmune; oral mucosal lesions; immunofluorescence positive for sub-basement membrane IgG/C3Urgent ophthalmology — systemic immunosuppression; biopsy for diagnosis
Neonatal Conjunctivitis — GonococcalOnset within 2–5 days of birth; profuse purulent discharge; corneal perforation risk; Gram stain diagnostic; earlier onset than chlamydial (5–14 days)Ocular emergency — systemic ceftriaxone; ophthalmology and paediatrics urgently
  • “Chronic conjunctivitis failing topical antibiotics in a young adult = chlamydia until proven otherwise” — topical antibiotics are entirely ineffective for C. trachomatis; any case of follicular conjunctivitis lasting >2–4 weeks that fails multiple topical antibiotic courses should trigger NAAT testing and systemic treatment
  • Take a sexual history in every young adult with chronic conjunctivitis — AIC is frequently missed because clinicians fail to ask; a non-judgemental, direct enquiry about recent sexual partners, STI history, and genital symptoms is a mandatory step in the workup of chronic follicular conjunctivitis
  • Always palpate the preauricular lymph node — tender preauricular lymphadenopathy in a young adult with follicular conjunctivitis points strongly toward an infectious aetiology (chlamydial or viral); its absence in a patient with unilateral chronic conjunctivitis should not exclude the diagnosis
  • Treat the patient and all current partners simultaneously — re-infection from an untreated partner is the single most common cause of apparent treatment failure in AIC; partner treatment is not optional — it is the cornerstone of management
  • Never diagnose chlamydial conjunctivitis without NAAT confirmation — the clinical picture overlaps significantly with viral conjunctivitis and other follicular reactions; NAAT of a conjunctival swab (and concurrent urogenital swab) is the diagnostic standard; empirical treatment without confirmation should only be considered when STI exposure is clearly established and testing is not immediately available
  • Neonatal conjunctivitis at 5–14 days = chlamydial until proven otherwise — the onset window is critical: chemical (day 1), gonococcal (days 2–5), chlamydial (days 5–14); any neonate with conjunctivitis requires urgent paediatric and ophthalmological assessment; oral erythromycin is essential to prevent chlamydial pneumonitis
  • In trachoma-endemic communities, Arlt’s line and Herbert’s pits are diagnostic of prior disease — these signs on slit lamp examination in a patient from an endemic region confirm chlamydial aetiology; Herbert’s pits (limbal depressions) and Arlt’s line (tarsal horizontal white band) are pathognomonic and persist long after active infection has resolved
  • Trichiasis in a trachoma patient requires surgical referral — not just epilation — repeated manual epilation provides temporary relief but worsens follicular re-growth of distorted lashes; bilamellar tarsal rotation surgery is the definitive treatment and prevents the corneal abrasion that ultimately causes blindness
  1. Thylefors B, Dawson CR, Jones BR, West SK, Taylor HR. A simple system for the assessment of trachoma and its complications. Bull World Health Organ. 1987;65(4):477–483.
  2. World Health Organization. Trachoma. WHO fact sheet. Geneva: WHO; 2022. Available from: https://www.who.int/news-room/fact-sheets/detail/trachoma
  3. Burton MJ, Rajak SN, Bauer J, Weiss HA, Tolbert SB, Bailey RL, et al. Conjunctival transcriptome in scarring trachoma. Infect Immun. 2011;79(1):499–511.
  4. Mariotti SP, Pascolini D, Rose-Nussbaumer J. Trachoma: global magnitude of a preventable cause of blindness. Br J Ophthalmol. 2009;93(5):563–568.
  5. Darougar S, Viswalingam M, Treharne JD, Kinnison JR, Jones BR. Sites of chlamydial infection in patients with ocular chlamydial infection. Br J Vener Dis. 1978;54(2):109–113.
  6. Mabey D, Fraser-Hurt N, Powell C. Antibiotics for trachoma. Cochrane Database Syst Rev. 2005;(2):CD001860.
  7. Schachter J, Dawson CR. Human Chlamydial Infections. Littleton, MA: PSG Publishing; 1978.
  8. Kohlhoff SA, Hammerschlag MR. Treatment of chlamydial infections: 2014 update. Expert Opin Pharmacother. 2015;16(2):205–212.
  9. Centers for Disease Control and Prevention. Sexually transmitted infections treatment guidelines, 2021: Chlamydial infections. MMWR Recomm Rep. 2021;70(4):1–187.
  10. Hammerschlag MR. Neonatal conjunctivitis. Pediatr Ann. 1993;22(6):346–351.
  11. Dean D, Rothschild J, Ruettger A, Kandel RP, Bhatta RC. Zoonotic Chlamydiaceae species associated with trachoma, Nepal. Emerg Infect Dis. 2013;19(12):1948–1955.
  12. Solomon AW, Holland MJ, Alexander ND, Massae PA, Aguirre A, Natividad-Sancho A, et al. Mass treatment with single-dose azithromycin for trachoma. N Engl J Med. 2004;351(19):1962–1971.
  13. West SK, Muñoz B, Mkocha H, Holland MJ, Aguirre A, Solomon AW, et al. Infection with Chlamydia trachomatis after mass drug administration for trachoma: a longitudinal study. Lancet. 2005;366(9493):1296–1300.
  14. Rajak SN, Habtamu E, Weiss HA, Kello AB, Gebre T, Genet A, et al. Epilation for trachomatous trichiasis and the risk of corneal opacification. Ophthalmology. 2012;119(1):84–89.
  15. Gambhir M, Basáñez MG, Turner F, Kumaresan J, Grassly NC. Trachoma: transmission, infection, and control. Lancet Infect Dis. 2007;7(6):420–427.
  16. Azari AA, Barney NP. Conjunctivitis: a systematic review of diagnosis and treatment. JAMA. 2013;310(16):1721–1729.
  17. Woodland RM, Darougar S, Thaker U, Cornell L, Siddiqui N, Wania M, et al. Causes of conjunctivitis and keratoconjunctivitis in Karachi, Pakistan. Trans R Soc Trop Med Hyg. 1992;86(3):317–320.
  18. Ross JDC, Jensen JS. Mycoplasma genitalium as a sexually transmitted infection: implications for screening, testing, and treatment. Sex Transm Infect. 2006;82(4):269–271.
  19. Singapore Optometric Association. Scope of practice guidelines for optometrists in Singapore. Singapore: Singapore Optometric Association; 2022.
  20. Ministry of Health Singapore. Infectious Diseases Act (Chapter 137). Singapore: Ministry of Health; 2008 (revised 2021).

Disclaimer: This guide is for educational purposes and clinical reference. Always exercise professional judgment and follow local regulations and scope of practice guidelines. Refer to ophthalmology when appropriate for complex cases or when outside the optometric scope of practice.